Bruker has announced the planned discontinuation of the IsoSpark and IsoLight platforms. Customers with questions about transition options and last-time-buy opportunities should contact their Bruker sales representative.

All Resources
Application Highlight
Employing PSI™ to Identify Optimal Bi-Specific Antibody Candidates

Learn how our PSI helps you reveal functional immune-tumor interaction and mechanism of therapy to advise lead choice.

What's Inside

In this Application Highlight we discuss:

The use of Polyfunctional Strength Index (PSI) a single-cell cytokine-based metric of cellular potency, in the context of pre-clinical assessment of bispecific antibodies
Identify subtle differences in quality of novel bispecific antibody constructs relative to controls, utilizing the PSI of the potent T cell subsets engaged
Demonstrate that PSI can improve the choice of lead bispecific immunotherapeutic products by identifying key differences in the therapies’ cytokine-based mechanisms at the single-cell level
A Deeper Look

More about this Application Highlight

Application of Bispecific Antibody Constructs to Improve Immunotherapy Success

Recent clinical progress in immuno-oncology significantly improved clinical outcomes for many patients with hard-to-treat malignant tumors, leading to partial and complete remission and long-term survival in a fraction of patients.

However, a large number of patients do not respond to these treatments, creating an urgent need for novel strategies to enhance the efficacy of immunotherapies.

Download this App Note to see how our PSI helps you overcome these challenges.

Row rect Shape Decorative svg added to top
Get the Application Highlight
Back to the Top